VUM02 Injection for steroid-resistant graft-versus-host disease
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an injection called VUM02 for people who have developed graft-versus-host disease (aGvHD) after a stem cell transplant and whose condition did not improve with standard steroid treatment. The goal is to see if VUM02 can help control the reaction.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You had a stem cell transplant for a blood cancer and then developed moderate to severe graft-versus-host disease (aGvHD) that did not get better with steroids.
- Your doctor expects you to live at least 3 more months.
- You have symptoms like rash, nausea, vomiting, diarrhea, or jaundice that are caused by aGvHD, not other conditions.
- You are able to start the study treatment within 3 days of joining.
- You do not have active infections like hepatitis B, C, HIV, or certain severe complications.
- You are not pregnant or planning pregnancy and agree to use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
This trial tests a new medicine called CK0802 for patients whose graft versus host disease (a complication after bone marrow transplant) did not improve with standard steroid treatment. The goal is to see if CK0802 can help control this condition when steroids alone haven't worked.
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
This study tests two medications (belumosudil and ruxolitinib) together for chronic graft-versus-host disease (cGvHD)—a condition where transplanted immune cells attack your body—that did not improve with steroid treatment alone. The trial aims to help patients whose disease is resistant to standard steroids.
This trial tests a combination of a steroid and a humanized antibody (called CD25 monoclonal antibody) as the first treatment for moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if this combination is safer and more effective than steroids alone.
Hear when a new Steroid-refractory Acute Graft-versus-host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.